Press Oliver W
Division of Medical Oncology, University of Washington Medical Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Semin Oncol. 2003 Apr;30(2 Suppl 4):10-21. doi: 10.1053/sonc.2003.23798.
One of the most promising therapeutic approaches currently under investigation for low-grade non-Hodgkin's lymphoma is the administration of monoclonal antibodies that recognize tumor-associated antigens. These antibodies can be used either in unmodified form or conjugated to cytotoxic drugs, toxins, or radionuclides. To date, the most promising of the immunoconjugates are radiolabeled antibodies. Radioimmunotherapy is an attractive approach because radiolabeled antibodies are effective even in the face of defective host immune effector function, antigen-negative variants, and poor penetration of the antibody into tumors. Iodine-131-and Yttrium-90-conjugated antibodies have shown superior response rates compared with unconjugated antibodies and have produced complete responses in 15% to 40% of treated patients. A variety of treatment approaches are currently being investigated, including administering radiolabeled antibodies in combination with chemotherapy and administering myeloablative doses with stem-cell rescue. This latter strategy has yielded complete remissions in the majority of treated patients, some durable for more than 5 years.
目前正在研究的针对低度非霍奇金淋巴瘤最有前景的治疗方法之一是给予识别肿瘤相关抗原的单克隆抗体。这些抗体可以以未修饰的形式使用，也可以与细胞毒性药物、毒素或放射性核素偶联。迄今为止，最有前景的免疫偶联物是放射性标记抗体。放射免疫疗法是一种有吸引力的方法，因为即使面对宿主免疫效应功能缺陷、抗原阴性变体以及抗体对肿瘤的穿透性差等情况，放射性标记抗体仍然有效。与未偶联抗体相比，碘 - 131和钇 - 90偶联抗体显示出更高的缓解率，并且在15%至40%的接受治疗的患者中产生了完全缓解。目前正在研究多种治疗方法，包括将放射性标记抗体与化疗联合使用以及给予清髓剂量并进行干细胞救援。后一种策略在大多数接受治疗的患者中产生了完全缓解，有些缓解持续超过5年。
